Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

Multiple sclerosis is a chronic disease that leads to disability at the young, working age. Disease-modifying treatment are used to control multiple sclerosis. There are two models of therapy: escalation and induction. Recently, many experts have given preference to an induction approach to treatment, when highly effective drugs are prescribed as early as possible. One promising direction is parenteral anti- B cell therapy. The history of the development of this drug group begins with the successful use of Rituximab for the treatment of patients with multiple sclerosis. The results of the study were so impressive that this was the reason for prescribing this therapy off-lable in routine practice. And we are now noticing an increase in the number of patients on therapy with the Rituximab in European countries. Subsequently, the Ocrelizumab was developed, which became the first and only drug for the treatment of primary progressive multiple sclerosis. Divosilimab (Russian-made drug) was registered in 2023, which is also considered original due to the specific modified glycosylation scheme of the Fc-fragment. Having a sufficient selection of highly effective drugs, we must remember that in the pursuit of effectiveness we must not forget about the safety of the therapy. The issues of the possible use of an extended administration interval and reduction of the used dosage with long-term use of this type of therapy are discussed.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

Cited by 3 publications

References 7 publications

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

The first experience with the use of divozilimab in the treatment of multiple sclerosis patients in daily clinical practice

Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab

Contact Info

Product

Resources

About